Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure

[1]  J. Nicholl,et al.  Noninvasive ventilation in acute cardiogenic pulmonary edema. , 2008, The New England journal of medicine.

[2]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[3]  J. McMurray,et al.  Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure , 2007, European journal of heart failure.

[4]  Nick Freemantle,et al.  Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a pre-defined analysis from the CARE-HF trial. , 2007, European heart journal.

[5]  A. Rigby,et al.  The effects of initiation or continuation of statin therapy on cholesterol level and all-cause mortality after the diagnosis of left ventricular systolic dysfunction. , 2007, American heart journal.

[6]  J. Cleland,et al.  Cardiac resynchronization therapy or atrio-biventricular pacing—what should it be called? , 2007, Nature Clinical Practice Cardiovascular Medicine.

[7]  W. Abraham,et al.  Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluatio , 2006, American heart journal.

[8]  R. Fernandez,et al.  Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. , 2005, JAMA.

[9]  J. McMurray,et al.  A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics , 2005, European journal of heart failure.

[10]  Jeroen J. Bax,et al.  How to predict response to cardiac resynchronization therapy? , 2005, European heart journal.

[11]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[12]  Christophe Leclercq,et al.  Predictors of response to cardiac resynchronization therapy (PROSPECT)--study design. , 2005, American heart journal.

[13]  L. Tavazzi,et al.  Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure , 2004, European journal of heart failure.

[14]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[15]  N. Freemantle,et al.  The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. , 2003, European heart journal.

[16]  S. Goodman,et al.  Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. , 2003, JAMA.

[17]  A. Stanton.  Therapeutic Potential of Renin Inhibitors in the Management of Cardiovascular Disorders , 2003, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[18]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[19]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[20]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[21]  O. Faergeman,et al.  The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. , 1997, Journal of cardiac failure.

[22]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.